Improved pharmacokinetics of AMG 517 through co-crystallization part 2: analysis of 12 carboxylic acid co-crystals.

Intrinsic dissolution, powder dissolution, and the pharmacokinetics (PK) of 12 carboxylic acid co-crystals of AMG 517 were determined and compared. Dissolution studies were performed in fasted simulated intestinal fluid (FaSIF). A control dissolution experiment was conducted with the free base in FaSIF plus sorbic acid to compare with the AMG 517 sorbic acid co-crystal (SRA). Suspension formulations in 1% polyvinylpyrrolidone K25 in water were administered orally at 100 mg/kg to rats. All co-crystals were found to have faster intrinsic and powder dissolution rates in FaSIF as well as higher area under the concentration-time curves (AUC) in rat PK investigations compared with the free base. The control dissolution experiment indicates that the increase in dissolution rate of SRA over the free base is not due to the presence of sorbic acid in the dissolution medium. Linear correlation of dissolution rate and AUC among the 12 co-crystals was moderate, indicating that in vitro dissolution is a valuable method to predict whether a co-crystal will improve the exposure of a poorly soluble pharmaceutical ingredient; however, in vivo testing may be required to determine the extent.

[1]  A. Cheng,et al.  Preparation, solid state characterization, and single crystal structure analysis of N-(4-(6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yloxy)benzo[d]thiazol-2-yl)acetamide crystal forms , 2011 .

[2]  J. C. Price,et al.  Accelerated Dissolution Testing for Controlled Release Microspheres Using the Flow-Through Dissolution Apparatus , 2009, Pharmaceutical development and technology.

[3]  A. Bak,et al.  Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals , 2008 .

[4]  Michael J Zaworotko,et al.  Expanding the scope of crystal form evaluation in pharmaceutical science. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[5]  L. Lesko,et al.  The Relative Bioavailability and In Vivo-In Vitro Correlations for Four Marketed Carbamazepine Tablets , 1998, Pharmaceutical Research.

[6]  Miranda L. Cheney,et al.  Effects of Crystal Form on Solubility and Pharmacokinetics: A Crystal Engineering Case Study of Lamotrigine , 2010 .

[7]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[8]  Matthew L Peterson,et al.  Improved pharmacokinetics of AMG 517 through co-crystallization. Part 1: comparison of two acids with corresponding amide co-crystals. , 2010, Journal of pharmaceutical sciences.

[9]  V. Saxena,et al.  Developability assessment in pharmaceutical industry: An integrated group approach for selecting developable candidates. , 2009, Journal of pharmaceutical sciences.

[10]  C A Hirsch,et al.  Fenoprofen: drug form selection and preformulation stability studies. , 1978, Journal of pharmaceutical sciences.

[11]  Kenneth R. Morris,et al.  An integrated approach to the selection of optimal salt form for a new drug candidate , 1994 .

[12]  N. Chen,et al.  Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. , 2007, Journal of medicinal chemistry.

[13]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[14]  O. Almarsson,et al.  Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. , 2007, Journal of pharmaceutical sciences.

[15]  M. Faul,et al.  Salt form selection and characterization of LY333531 mesylate monohydrate. , 2000, International journal of pharmaceutics.

[16]  A. Bak,et al.  Drug Substance and Former Structure Property Relationships in 15 Diverse Pharmaceutical Co-Crystals , 2009 .

[17]  A. Weiner,et al.  Controlled Flow-Through Dissolution Methodology: A High-Performance System , 2008 .

[18]  Sekhar Surapaneni,et al.  The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. , 2008, Journal of pharmaceutical sciences.